XML 43 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Loss The following table sets forth our segment loss disclosure for the three months ended March 31, 2025 and 2024 (in thousands):

 

 

Three Months Ended
March 31,

 

 

2025

 

 

2024

 

R&D – Compensation and benefits (1)

 

$

3,294

 

 

$

3,487

 

R&D – Clinical trial costs

 

 

2,850

 

 

 

2,596

 

R&D – Outsourced services & Consulting

 

 

2,382

 

 

 

4,679

 

R&D – Lab and pharmacology supplies

 

 

290

 

 

 

704

 

R&D – Other costs (2)

 

 

597

 

 

 

433

 

G&A – Compensation and benefits (1)

 

 

1,574

 

 

 

1,547

 

G&A – Professional service fees

 

 

997

 

 

 

793

 

G&A – Insurance

 

 

218

 

 

 

30

 

G&A – Other costs (3)

 

 

726

 

 

 

372

 

Facilities related

 

 

2,299

 

 

 

652

 

Stock-based compensation and depreciation

 

 

2,114

 

 

 

1,590

 

Total operating expense

 

 

17,341

 

 

 

16,883

 

Loss from operations

 

 

(17,341

)

 

 

(16,883

)

Interest and other income, net

 

 

1,583

 

 

 

1,453

 

Segment net loss

 

$

(15,758

)

 

$

(15,430

)

 

(1)
Excludes stock-based compensation expense.
(2)
Includes software expense, database subscriptions expense, lab service contract expense, travel expense, and other miscellaneous expenses.
(3)
Includes travel expense, public & investor relations expense, software expense, employee training & development expense, and other miscellaneous expenses.